RT Journal Article
SR Electronic
T1 NANETS/SNMMI Procedure Standard for Somatostatin Receptor–Based Peptide Receptor Radionuclide Therapy with <sup>177</sup>Lu-DOTATATE
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 937
OP 943
DO 10.2967/jnumed.118.230607
VO 60
IS 7
A1 Thomas A. Hope
A1 Amanda Abbott
A1 Karen Colucci
A1 David L. Bushnell
A1 Linda Gardner
A1 William S. Graham
A1 Sheila Lindsay
A1 David C. Metz
A1 Daniel A. Pryma
A1 Michael G. Stabin
A1 Jonathan R. Strosberg
YR 2019
UL http://jnm.snmjournals.org/content/60/7/937.abstract
AB With the recent approval of 177Lu-DOTATATE for use in gastroenteropancreatic neuroendocrine tumors, access to peptide receptor radionuclide therapy is increasing. Representatives from the North American Neuroendocrine Tumor Society and the Society of Nuclear Medicine and Molecular Imaging collaborated to develop a practical consensus guideline for the administration of 177Lu-DOTATATE. In this paper, we discuss patient screening, maintenance somatostatin analog therapy requirements, treatment location and room preparation, drug administration, and patient release as well as strategies for radiation safety, toxicity monitoring, management of potential complications, and follow-up. Controversies regarding the role of radiation dosimetry are discussed as well. This document is designed to provide practical guidance on how to safely treat patients with this therapy.